Optiscan Imaging (ASX:OIL) is set to partner with Mayo Clinic to develop a cutting-edge digital confocal laser endomicroscopic imaging system specifically designed for use in robotic surgeries.
The collaboration brings together Optiscan’s expertise in engineering digital endomicroscopic hardware and software development with Mayo Clinic’s extensive knowledge in robotic surgery and commitment to patient care excellence.
Over the next 24 months, both companies will work closely to co-develop a robot-compatible endomicroscopic imaging system, initially focusing on its application in robotic-assisted breast cancer surgery.
Mayo Clinic is known as the largest integrated, not-for-profit medical group practice globally, and renowned for its dedication to transform healthcare and achieve superior patient outcomes. With numerous top rankings for high-quality patient care and extensive experience in surgical procedures, including over 4,000 robotic surgery cases annually, Mayo Clinic brings invaluable expertise to this collaboration.
“This collaboration is built on a shared history of innovation and a laser focus on delivering the highest quality patient outcomes for better health care delivery,” Optiscan CEO and Managing Director, Dr Camile Farah, said.
The market for robotic-assisted surgery is witnessing substantial growth. In the US alone, the robotic surgery service market was valued at US$1.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 17.3% to reach US$6.4 billion by 2030.
“This collaboration will provide surgeons with real-time microscopic information of cancer clearance for the potential to reduce missed cancers and minimise repeat surgeries due to residual disease,” Dr Farah added.
OIL has been trading at 12 cents.